Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents
出版年份 2021 全文链接
标题
Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents
作者
关键词
-
出版物
JOURNAL OF MEDICINAL CHEMISTRY
Volume 64, Issue 12, Pages 8447-8473
出版商
American Chemical Society (ACS)
发表日期
2021-06-08
DOI
10.1021/acs.jmedchem.1c00413
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Role of HDACs in normal and malignant hematopoiesis
- (2020) Pan Wang et al. Molecular Cancer
- Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy
- (2020) Tingting Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors
- (2020) Ashish Thakur et al. JOURNAL OF MEDICINAL CHEMISTRY
- Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
- (2020) Terence C. S. Ho et al. JOURNAL OF MEDICINAL CHEMISTRY
- Novel HDAC/Tubulin Dual Inhibitor: Design, Synthesis and Docking Studies of α-Phthalimido-Chalcone Hybrids as Potential Anticancer Agents with Apoptosis-Inducing Activity
- (2020) Ahmed A E Mourad et al. Drug Design Development and Therapy
- Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma
- (2020) Minjeong Yeon et al. Frontiers in Cell and Developmental Biology
- Design, synthesis, and bioevaluation of pyrazolo[1,5-a]pyrimidine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site with potent anticancer activities
- (2020) Gang Li et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment
- (2020) Xiaopeng Peng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of novel CA-4 analogs as dual inhibitors of tubulin polymerization and PD-1/PD-L1 interaction for cancer treatment
- (2020) Xuchao Yang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Multi-targeting Anticancer Agents: Rational Approaches, Synthetic Routes and Structure Activity Relationship
- (2019) Harbinder Singh et al. Anti-Cancer Agents in Medicinal Chemistry
- Oxazole-Bridged Combretastatin A-4 Derivatives with Tethered Hydroxamic Acids: Structure–Activity Relations of New Inhibitors of HDAC and/or Tubulin Function
- (2019) Florian Schmitt et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies
- (2019) Xuewu Liang et al. JOURNAL OF MEDICINAL CHEMISTRY
- An Overview of HDAC Inhibitors and their Synthetic Routes
- (2019) Xiaopeng Peng et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Synthesis and biological evaluation of paclitaxel and vorinostat co-prodrugs for overcoming drug resistance in cancer therapy in vitro
- (2019) Shuangxi Liu et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors
- (2019) Baolei Wang et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1H-Indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl) Methanone (ABI-231) Analogues Targeting the Colchicine Binding Site in Tubulin
- (2019) Qinghui Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design, synthesis, and biological evaluation of 1-substituted -2-aryl imidazoles targeting tubulin polymerization as potential anticancer agents
- (2019) Ling Li et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug
- (2019) Jingkao Chen et al. INVESTIGATIONAL NEW DRUGS
- Manipulating macrophage polarization and function using classical HDAC inhibitors: Implications for autoimmunity and inflammation
- (2018) Asadollah Mohammadi et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation
- (2018) Alshimaa M.A. Aboeldahab et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections
- (2018) Yahui Huang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on isocombretastatin A-4
- (2018) Diana Lamaa et al. JOURNAL OF MEDICINAL CHEMISTRY
- Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer
- (2018) Heba M. Hesham et al. MEDICINAL RESEARCH REVIEWS
- Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms
- (2018) Joachim Alexandre et al. PHARMACOLOGY & THERAPEUTICS
- Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities
- (2018) Avirup Guha et al. TRENDS IN CARDIOVASCULAR MEDICINE
- A Novel Dual HDAC6 and Tubulin Inhibitor, MPT0B451, Displays Anti-tumor Ability in Human Cancer Cells in Vitro and in Vivo
- (2018) Yi-Wen Wu et al. Frontiers in Pharmacology
- Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents
- (2018) Shipeng He et al. JOURNAL OF MEDICINAL CHEMISTRY
- Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors
- (2017) Guoqiang Dong et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat
- (2017) Chiara Zagni et al. MEDICINAL RESEARCH REVIEWS
- HDAC1-3 inhibitor MS-275 enhances IL10 expression in RAW264.7 macrophages and reduces cigarette smoke-induced airway inflammation in mice
- (2017) Niek G. J. Leus et al. Scientific Reports
- Inhibitors of histone deacetylase as antitumor agents: A critical review
- (2016) Mohammed Manal et al. BIOORGANIC CHEMISTRY
- 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
- (2016) Jose Luis Zamorano et al. EUROPEAN HEART JOURNAL
- Cardiovascular effects of histone deacetylase inhibitors epigenetic therapies: Systematic review of 62 studies and new hypotheses for future research
- (2016) Gabriele Giacomo Schiattarella et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Antitumor Activity of Lankacidin Group Antibiotics Is Due to Microtubule Stabilization via a Paclitaxel-like Mechanism
- (2016) Ahmed Taha Ayoub et al. JOURNAL OF MEDICINAL CHEMISTRY
- HDACs and HDAC Inhibitors in Cancer Development and Therapy
- (2016) Yixuan Li et al. Cold Spring Harbor Perspectives in Medicine
- Histone deacetylase inhibitors in hematological malignancies and solid tumors
- (2015) Pusoon Chun ARCHIVES OF PHARMACAL RESEARCH
- Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors
- (2015) Xuan Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Epigenetic linkage of aging, cancer and nutrition
- (2015) M. Daniel et al. JOURNAL OF EXPERIMENTAL BIOLOGY
- The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo
- (2015) Min-Wu Chao et al. Journal of Hematology & Oncology
- Transgenerational epigenetic inheritance: an open discussion
- (2015) Corina Nagy et al. Epigenomics
- Epigenetic treatment of solid tumours: a review of clinical trials
- (2015) Clara Nervi et al. Clinical Epigenetics
- Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin
- (2015) Philip T. Sager et al. Cancer Medicine
- Targeting Histone Deacetylases for Cancer Therapy: From Molecular Mechanisms to Clinical Implications
- (2014) Zhiming Li et al. International Journal of Biological Sciences
- New and emerging HDAC inhibitors for cancer treatment
- (2014) Alison C. West et al. JOURNAL OF CLINICAL INVESTIGATION
- Epigenetics: Novel Therapeutics Targeting Epigenetics
- (2014) Stuart J. Conway et al. JOURNAL OF MEDICINAL CHEMISTRY
- Polypharmacology: Challenges and Opportunities in Drug Discovery
- (2014) Andrew Anighoro et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Novel Microtubule-Destabilizing Drug BAL27862 Binds to the Colchicine Site of Tubulin with Distinct Effects on Microtubule Organization
- (2014) Andrea E. Prota et al. JOURNAL OF MOLECULAR BIOLOGY
- Targeting Microtubules by Natural Agents for Cancer Therapy
- (2014) E. Mukhtar et al. MOLECULAR CANCER THERAPEUTICS
- Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
- (2014) Katrina J. Falkenberg et al. NATURE REVIEWS DRUG DISCOVERY
- QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review
- (2014) Marzia Locatelli et al. Targeted Oncology
- The discovery of colchicine-SAHA hybrids as a new class of antitumor agents
- (2013) Xuan Zhang et al. BIOORGANIC & MEDICINAL CHEMISTRY
- A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer
- (2013) Dana E. Rathkopf et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability
- (2013) Benjamin E. L. Lauffer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Polypharmacology – Foe or Friend?
- (2013) Jens-Uwe Peters JOURNAL OF MEDICINAL CHEMISTRY
- Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
- (2013) J Minami et al. LEUKEMIA
- RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells
- (2013) Y Zhu et al. ONCOGENE
- Discovery of Novel 2-Aryl-4-benzoyl-imidazole (ABI-III) Analogues Targeting Tubulin Polymerization As Antiproliferative Agents
- (2012) Jianjun Chen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Histone deacetylases and cancer
- (2012) Bruna Barneda-Zahonero et al. Molecular Oncology
- Epigenetic protein families: a new frontier for drug discovery
- (2012) Cheryl H. Arrowsmith et al. NATURE REVIEWS DRUG DISCOVERY
- CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity
- (2010) Cheng-Jung Lai et al. CANCER RESEARCH
- Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
- (2010) Cliona Grant et al. Expert Review of Anticancer Therapy
- Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer
- (2010) Xiong Cai et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Novel 2-Aryl-4-benzoyl-imidazoles Targeting the Colchicines Binding Site in Tubulin As Potential Anticancer Agents
- (2010) Jianjun Chen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Microtubule-binding agents: a dynamic field of cancer therapeutics
- (2010) Charles Dumontet et al. NATURE REVIEWS DRUG DISCOVERY
- Discovery of 4-Substituted Methoxybenzoyl-aryl-thiazole as Novel Anticancer Agents: Synthesis, Biological Evaluation, and Structure−Activity Relationships
- (2009) Yan Lu et al. JOURNAL OF MEDICINAL CHEMISTRY
- HDAC inhibitors in models of inflammation-related tumorigenesis
- (2008) Rainer Glauben et al. CANCER LETTERS
- HDAC family: What are the cancer relevant targets?
- (2008) Olaf Witt et al. CANCER LETTERS
- Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models
- (2008) Shuzhen Liu et al. MOLECULAR CANCER THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started